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1  | INTRODUC TION
Cirrhosis is the end result of chronic liver disease. It affects over 
600 000 adults in the USA, with estimates that an additional five 
million have at least bridging fibrosis.1,2 These numbers will rise as 
baby boomers with chronic hepatitis C age and the incidence of 
nonalcoholic fatty liver disease grows.3 Indeed, patients with cirrho-
sis seeking medical attention has increased by 59% over the past 
decade,4 and cirrhosis is now the 12th leading cause of death in the 
USA.5 Compounding the problem of rising prevalence, cirrhosis is an 
expensive condition, with an estimated annual healthcare cost of $2 
billion dollars in the USA.6
The primary drivers of morbidity and cost in cirrhosis are compli-
cations of decompensated disease: ascites, hepatic encephalopathy 
(HE) and variceal hemorrhage. Patients are frequently hospitalized 
for these conditions, with high 30- day readmission rates ranging 
from 25%- 52%.7,8 Providers prescribe a variety of medications with 
narrow therapeutic windows to treat these complications. Even for 
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Abstract
Cirrhosis is a morbid condition associated with frequent hospitalizations and high 
mortality. Management of cirrhosis requires complex medication regimens to treat 
underlying liver disease, complications of cirrhosis and comorbid conditions. This re-
view examines the complexities of medication management in cirrhosis, barriers to 
optimal medication use, and potential interventions to streamline medication regi-
mens and avoid medication errors. A literature review was performed by searching 
PUBMED through December 2017 and article reference lists to identify articles rel-
evant to medication management, complications, adherence, and interventions to 
improve medication use in cirrhosis. The structural barriers in cirrhosis include sheer 
medication complexity related to the number of medications and potential for cogni-
tive impairment in this population, faulty medication reconciliation and limited ad-
herence. Tested interventions have included patient self- education, provider driven 
patient education, intensive case management including medication blister packs and 
smartphone applications. Initiatives are needed to improve patient, caregiver and 
provider education on appropriate use of medications in patients with cirrhosis. A 
multidisciplinary team should be established to coordinate care with close monitor-
ing, address patient and caregiver concerns, and to provide timely access to outpa-
tient evaluation of urgent/complex issues. Future studies evaluating the clinical 
outcomes and cost effectiveness of interventions are needed.
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the most experienced provider, managing these medications is chal-
lenging. The risks of medication errors and serious side effects are 
magnified by difficulties with patient adherence, medication inter-
actions, and the need for frequent dosage adjustments. Herein, we 
review the data on challenges and solutions for optimal medication 
management in patients with cirrhosis.
2  | METHODS
A literature review was performed by searching PUBMED for rele-
vant full text articles through December 2017. The authors searched 
for articles using keywords: cirrhosis, end- stage liver disease, drug 
therapy, medication errors, medication adherence, medication rec-
onciliation, patient education, disease management, case manage-
ment. An additional search of article reference lists was performed 
to identify further studies. Only English language publications were 
considered.
3  | COMPLIC ATIONS OF MEDIC AL 
THER APY
This section reviews the special considerations that need to be made 
when using routine, even over- the- counter, medications in patients 
with cirrhosis (Table 1).
3.1 | Diuretics
As many as 58% of patients with decompensated cirrhosis will develop 
ascites.9 Few patients manage to adhere to the recommended two- gram 
sodium diet, and salt restriction alone is insufficient for many. Diuretic 
use requires vigilance to balance volume control vs the risks of over 
diuresis leading to electrolyte imbalance and acute kidney injury (AKI). 
Firstly, patients need to have monitoring of their electrolytes and renal 
function. Active, anticipatory management demands patients getting 
regular labs, substantial non- reimbursed time to co- ordinate testing, 
and a medical team to follow up results. Up to 22% of readmissions after 
discharge for cirrhosis complications are attributable to AKI, hypona-
tremia, and hypo(or hyper)kalemia.8,10 Secondly, diuretic therapy needs 
frequent adjustments. To accurately assess volume status, patients are 
asked to record their daily weights but many don’t and dose adjustments 
based on patient- reported swelling can be flawed. Whereas the com-
plexities of warfarin adjustments are handled by anticoagulation clinics 
making dose adjustments based on standardized labs, systems of care 
for diuretics are lacking, and depend not only on labs but also on clinical 
assessment. An example of how AKI can occur in the course of seem-
ingly routine care for patients with cirrhosis is laid out in Figure 1.
3.2 | Lactulose and rifaximin
HE affects up to 40% of patients with decompensated cirrhosis.11 
Lactulose and rifaximin are the principal pharmacological therapies 
for HE. Lactulose must be taken several times a day, titrated to yield 
at least 2- 3 bowel movements daily.12 One missed dose may cause a 
downward spiral of progressive confusion, leading to further missed 
doses and worsening HE. Furthermore, lactulose is associated with 
abdominal cramping, and frequent loose stools (a desired effect) 
which contribute to poor adherence.13 Rifaximin, a poorly absorb-
able antibiotic,12 is well- tolerated and has been shown to reduce 
hospital readmissions.14,15 Still, only 60% of patients with overt HE 
are prescribed rifaximin.16 Although rifaximin is generally cost sav-
ing in patients with a prior hospitalization for overt HE by reducing 
readmissions, coverage by insurers remains limited.17
3.3 | Beta blockers
Non- selective beta- blockers (NSBBs) can prevent variceal hemorrhage 
in patients with large varices. Ideally, the dose should be titrated to 
decrease hepatic vein portal pressure gradient to <12 mm Hg or a de-
crease in 20% from baseline, but these measurements are not widely 
available.18 In clinical practice, the dose of NSBB is titrated to decrease 
the resting heart rate to 55- 60 beats per minute,18 a target achieved 
by only 9.8% of patients.19 Inadequate dosage accounts for treatment 
failure (variceal hemorrhage) and may be a result of lack of monitoring 
during clinical follow- up. In addition, NSBBs cause a myriad of side ef-
fects including fatigue, depression, sexual dysfunction and orthostasis. 
Though controversial, NSBBs may increase the risk of AKI in patients 
with ascites, particularly those with baseline hypotension.20,21
3.4 | Proton pump inhibitors (PPIs)
PPIs are one of the most widely prescribed medications.22 They often 
are started for a specific indication, and continued without reviewing 
if they are still needed. Up to 63% of patients with end- stage liver 
Key points
• Providers should be aware of the known adverse effects 
of medications used to treat complications of cirrhosis, 
in addition to the adverse effects for routinely used 
medications in this population.
• Complex medication regimens and medication list dis-
crepancies are common in cirrhosis. Other factors that 
limit optimal and safe medication use include impaired 
cognition related to cirrhosis, medication adverse ef-
fects, suboptimal adherence and provider knowledge 
gaps.
• Patient education, case management and novel tech-
nologies can be used to overcome these barriers. 
Restructuring delivery of care to include a multidiscipli-
nary team approach and ensuring timely access to out-
patient care is also needed.
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disease (ESLD) on PPIs are prescribed them inappropriately, for ex-
ample as long- term therapy after variceal bleeding (where reflexive 
in- hospital management of bleeding is continued on discharge).23,24 
There is growing concern that chronic use is associated with adverse 
effects specific to patients with cirrhosis. PPI use and spontaneous 
bacterial peritonitis (SBP) have been associated in a meta- analysis, 
possibly because PPIs increase the risk of small intestinal bacterial 
overgrowth which, in turn, leads to bacterial translocation and SBP.25 
In addition, patients with cirrhosis on a PPI have an increased risk of C. 
difficile infection.26 Through similar adverse changes in the gut micro-
biome, PPIs may increase the risk of HE and readmission to hospital.27
4  | STRUC TUR AL BARRIERS TO OPTIMAL 
MEDIC ATION MANAGEMENT
4.1 | Medication complexity
Patients with cirrhosis including some with compensated cirrho-
sis are on multiple medications with an average between 3 and 
10 medications.13,28,29 Volk et al showed that in patients with 
cirrhosis, the number of medications at discharge can predict time 
to readmission.29 In addition to the number of medications, dos-
ing frequency and the need to actively titrate by symptom and 
effect make medication regimens for patients with cirrhosis com-
plex. This is further complicated in patients with HE where im-
paired cognition limits the ability of patients to remember to take 
their medications and to adjust dosing according to their response. 
While caregivers can help assess responses to some medications 
such as body weight for diuretics, recording the number of bowel 
movements in response to lactulose is more difficult and reliant on 
patient reporting.
4.2 | Medication list discrepancies and faulty 
reconciliation
Patients often have medications prescribed by more than one doctor 
who do not have the complete medication list and are not necessar-
ily aware of the changes made by other providers. When patients are 
hospitalized, medications are often started, adjusted or stopped with 
limited teaching and reconciliation at the time of care transitions. 
TABLE  1 Commonly used medications and adverse effects in cirrhosis
Medication class Indication Take home point Adverse effects
NSAIDs Acute and chronic 
pain
Readily available and often prescribed first line, but 
should not be used in the presence of ascites50
AKI 
Gastrointestinal bleeding
Acetaminophen Lower daily dose (≤2000 mg daily) is safe to use51 and 
preferred first line pain medication
Acute liver injury/failure with higher 
than recommended doses
Narcotics Commonly prescribed (19%- 60% of patients)52,53 Constipation
HE
Drug dependence
Proton Pump 
Inhibitors
GERD, PUD, 
dyspepsia
Long term PPI use is often not indicated, up to 63% of 
patients are continued on a PPI indefinitely after a 
variceal bleed23
Potential association with Spontaneous 
Bacterial Peritonitis, HE10,25
C. difficile infection26
Statins Cardiovascular risk 
reduction
Statins have been shown to be safe in compensated 
cirrhosis and should be continued as clinically 
indicated. Recent studies suggest they may be 
beneficial in patients with cirrhosis 54,55
Elevated liver enzymes (only clinically 
significant if bilirubin is elevated, which 
is rare)54
Myalgias
AKI, Acute Kidney Injury; GERD, Gastroesophageal reflux disease; HE, Hepatic Encephalopathy; NSAIDs, Non- Steroidal Anti- Inflammatory Drugs; PPI, 
Proton Pump Inhibitors; PUD, Peptic ulcer disease.
F IGURE  1 Downward spiral of adverse medication effects. HE, Hepatic Encephalopathy; NSAIDs, Non- Steroidal Anti- inflammatory 
Drug; NSBB, Non- selective Beta Blocker
     |  1885THOMSON eT al.
The result is confusion which can lead to patient harm and read-
missions. Pharmacy support for high- risk patients has been shown 
to decrease discrepancies, but it is unclear if decreased medication 
discrepancies leads to decreased healthcare utilization or improves 
patient outcomes.30 Hayward et al compared the dose, frequency 
and indications of each medication reported by a group of 50 pa-
tients with cirrhosis with a state- wide pharmacy record. Significant 
discrepancies were adjudicated by a panel of hepatologists (Table 2). 
Half of the patients had significant discrepancies with the potential 
for patient harm within 7 days. Discrepancies were associated with 
older age, taking ≥5 medications each day, and lower medication 
adherence (according to the Morisky Medication Adherence Scale 
[MMAS- 8 score]).31 This study reinforces the importance of ask-
ing about over the counter or complementary medications, as only 
31.8% of these medications were listed by patients without specific 
inquiry. It also highlights the need for structured patient education 
because only half of the patients reported being told how to take 
their medications and less than a third of the patients taking diuret-
ics knew they should keep a record of their weight. This study was 
limited by patient recall as most patients did not bring their medica-
tion list in, and caregivers were not always present to help verify 
medications.32
4.3 | Medication adherence
Broadly, adherence is related to the complexity of the regimen, side 
effects, costs and patient understanding of the indications, regimen 
and possible side effects. Measuring adherence is challenging in 
clinical and research settings as there are different criteria for what 
is considered “adherent” and no gold standard to measure it. With 
this in mind, adherence rates for patients in the general population 
with chronic conditions range between 43% and 78%.33 Adherence 
rates are around 72% when patient reported measures are used.34
Polis et al examined complete medication regimen adherence 
surveying 29 cognitively intact patients with Child A- B cirrhosis. 
These patients had been hospitalized at least once and were taking 
3.2 medications on average. There are several key points from this 
study. Firstly, 54% of the patients reported that they missed at least 
one dose of their medications during the past 30 days. Reasons for 
missed doses included forgetfulness (42%), being away from home/
change in routine (36%), sleeping through the dose time (32%) and 
running out of medications (25%). Conversely, adherence was asso-
ciated with patients reporting less fatigue, less abdominal symptoms 
(such as pain, bloating) and higher emotional well- being. Secondly, 
only 62% of patients answered more than 75% of the questions 
TABLE  2 Medication adherence in the pre- and post- liver transplant patient population
Article
Patient popula-
tion; n Adherence measure Significant findings
Affecting clinical 
outcomes?
Hayward 201632 Cirrhosis n = 50; 
40% 
decompensated
Self- reported medication list 
compared to medical record
54% had ≥1 and 24% had ≥3 discrepancies 
between what patients were taking and 
the prescribed regimens
Not measured
Leevy 200735 Hepatic 
encephalopathy 
n = 145; 95% 
with cirrhosis, 
12% on 
transplant list
Retrospective review of medical 
record
92% took rifaximin for >75% of prescribed 
doses 
30% took lactulose for >75% of prescribed 
doses
Fewer hospitali-
zations and 
hospital days 
when patients 
were taking 
rifaximin
Polis 201528 Cirrhosis, n = 29; 
mean MELD 11
Patient response (MMAS- 8) 54% “sometimes forgot to take their 
medications” in the past 30 d 
29% had missed 1 or more medication over 
the last 2 wk
Not measured
Kuo 201613 Patients listed for 
liver transplant, 
n = 181; mean 
MELD 13
Patient response (MMAS- 8) 42% “sometimes forgot to take their 
medications”  
28% missed 1 or more medications in the 
past 2 wk 
12% missed 1 or more medications in the 
day prior
Not measured
Serper 201556 Liver transplant 
recipients, 
n = 105; median 
20 mo from 
transplant
Structured interviews to 
determine patient knowledge 
and self- reported use compared 
with medical record abstraction 
and tacrolimus blood levels
86% displayed correct medication 
treatment knowledge 
78% could demonstrate simulated regimen 
use to researchers 
14% self- reported as non- adherent 
32% non- adherence based on tacrolimus 
levels
Higher treatment 
knowledge 
scores and 
demonstrated 
regimen use 
associated with 
reduced 
readmissions 
after liver 
transplant
MELD, Model for End- Stage Liver Disease; MMAS- 8, Morisky Medication Adherence Scale.
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correctly on a quiz focused on disease knowledge and treatments. 
Higher scores were not associated with adherence. Thirdly, one in 
three patients stated they would adjust their medications if their 
symptoms improved without talking to their physicians.28
Cirrhosis specifically has many medications that can be partic-
ularly noxious, further limiting adherence (Table 2). For instance, 
Lactulose adherence, as measured by patients’ report of taking more 
than 75% of their prescribed doses, can be as low as 31%.35 The 
same study found that adherence to rifaximin use was 92%. The 
wide gap between taking more than 75% prescribed doses of lactu-
lose and rifaximin argues that the adverse effects of lactulose may 
have a larger effect on adherence than HE itself.
Medication adherence in liver transplant candidates has been 
closely studied because poor adherence to anti- rejection medica-
tions is thought to be a leading cause of graft failure. In a study 
evaluating medication compliance in patients awaiting liver trans-
plant, 70% of patients were “low adherers” to their medication reg-
imens defined as not having a perfect score (<8) on the MMAS- 8. 
The median number of medications taken in this cohort of patients 
was 7, not including supplements. Low- adherers were more likely 
to be diabetic, had a higher medication complexity judged by the 
MRCI score (Medication Regimen Complexity Index) and signifi-
cantly lower self- reported health. The most common reasons for 
not taking medications were forgetting to do so (27%) and side 
effects (14%). Lactulose was the medication that these patients 
were least likely to take. High medication burden was associated 
with non- adherence, while high MELD (Model for End- Stage Liver 
Disease) or Child- Pugh scores were not associated with adherence 
in multivariate analysis.13
5  | INTERVENTIONS TO IMPROVE 
MEDIC ATION MANAGEMENT
Congestive heart failure (CHF) is a similar disease model in that pa-
tients are medically complex and on multiple medications, which 
often include diuretics. Patients in this population have similar read-
mission rates as those with cirrhosis.36 Research in CHF has shown 
that interventions to improve medication adherence, such as inpa-
tient patient education, multidisciplinary care involvement, post- 
discharge clinic follow- up and tele- monitoring, improves mortality 
and readmission rates.37 The cost- effectiveness of these interven-
tions combined or used individually is not well- known.38,39 Building 
on this model, a multifaceted approach including patient and pro-
vider education, case management and delivery system redesign is 
needed to improve medication management in patients with cirrho-
sis. Detailed below are examples of interventions aimed at improving 
medication use in patients with ESLD (Table 3).
5.1 | Patient education
The simplest intervention is patient self- education. Larrey et al 
showed that frequent (5- 6 sessions over 48 weeks) nursing- led 
education visits for patients undergoing interferon and ribavi-
rin therapy for hepatitis C improved both adherence (69.7% vs 
53.%, P < .03) and sustained virological response rates (38.2% vs 
24.8%).40 35% of the included patients had extensive fibrosis, de-
fined as F3- F4 fibrosis. Though these regimens are outdated, their 
results show the downstream benefits of investing in nursing visits 
for patient education.
In decompensated cirrhosis. Volk et al gave patients with cir-
rhosis, 25% of whom were decompensated with HE, a booklet on 
prevention and management of complications of cirrhosis as well 
as health management topics such as surgery and hospitalizations. 
Patients took a quiz before and after receiving the booklet which 
focused on recommended salt intake and the safety of medications 
such as statins, acetaminophen, and NSAIDs (Non- Steroidal Anti- 
Inflammatory Drugs). Only 53% of the 15 questions were answered 
correctly at baseline, but the correct response rate rose significantly 
to 67% after the intervention.41 This is promising, but it is unknown 
whether this one- time intervention improved medication adherence 
or patient outcomes.
5.2 | Case management
Intensive outpatient case management and follow- up has also been 
evaluated to improve outcomes and to reduce hospital readmis-
sions. Wigg et al performed a randomized trial of a case manage-
ment program in patients discharged from the hospital with cirrhosis 
and ascites. Their multimodal intervention included a booklet with 
nursing- led education on management of ascites and encephalopa-
thy, medication blister packs, a post- discharge home- visit, weekly 
nurse phone calls, rapid access to care for patient concerns, and writ-
ten and telephone reminders before appointments. This interven-
tion did improve attendance at appointments and multiple process 
measures (hepatocellular carcinoma screening, transplant evaluation 
and hepatitis A/B vaccination), but it did not reduce the number of 
days patients spent in the hospital.42 Although the authors did not 
examine medication use or adherence specifically, this study under-
scores how chronic disease management with patient education on 
medication use can improve patient centred outcomes. Preventable 
readmissions are an important target for interventions to optimize 
medication management in cirrhosis, but using this as the only tar-
get may be missing other key outcomes. Kanwal et al found that 
improved contact with medical professionals was associated with 
increased hospital readmissions though mortality was decreased,43 
leading to the conclusion that readmissions to manage problems in 
earlier stages may be beneficial for patients.8
5.3 | Smart phone applications
Smart phone based applications (“apps”), such as the “Patient Buddy” 
have been adapted to improve medication use, with an emphasis on 
reducing admissions for HE. A pilot study enrolled 40 patients ad-
mitted for decompensated cirrhosis (most with HE) and their car-
egivers to receive an iPhone loaded with a cirrhosis modified Patient 
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Buddy app to track medications, sodium intake, weights and weekly 
cognitive assessments (assessed via orientation questions and the 
EncephalApp Stroop test44 performed by caregivers).45 Participants 
were educated on emergencies that should prompt them to reach 
out to their care team. Patients and caregivers were instructed to 
input the patient’s individual medication intake each day. If a critical 
medication entry was missing, an alert was delivered to the patient, 
caregiver and study team. The study team followed up for these 
alerts with a message via the application or a phone call. Caregiver 
identified changes in orientation questions or the EncephalApp 
results were classified as impending HE and expedited outpatient 
follow- up was arranged as needed. Overall, 42.5% of patients in this 
pilot study were readmitted within 30 days. However, no patients 
were admitted for HE.
6  | CONCLUSIONS
Medication management for patients with cirrhosis is complex and 
is associated with multiple risks, including but not limited to or-
thostatic hypotension, falls, worsening ascites and AKI (Figure 1). 
Optimal care requires coordinated follow- up with well- informed 
providers and close monitoring. In addition, efforts designed to pro-
mote patient self- management strategies and adherence while antic-
ipating the pitfalls presented by cognitive dysfunction and frequent 
hospitalization, and to educate and empower caregivers to assist in 
the care of patients should be implemented. The existing literature 
suggests patients with cirrhosis and a high medication burden are 
at highest risk for poor outcomes through ineffective medication 
management, but further work needs to be done identifying at risk 
patients. There are also large gaps in the literature evaluating medi-
cation interventions for this population. Conclusions can be drawn 
from similarities in CHF, but clearly more research needs to be done 
in cirrhosis. Future interventions should be evaluated for clinical and 
cost effectiveness.
On the basis of the existing evidence, the optimal solution 
would create a system where there is multidisciplinary involve-
ment (nurses, pharmacists and physicians) in the inpatient and 
outpatient settings, standardized post- hospitalization clinic visits, 
and easy access to providers (telephone or in- person) for patients 
concerns (Figure 2). Many aspects of this are included in the estab-
lished chronic care model,46 which focuses on active care between 
visits, mobilizing community support, enhancing patient self- 
management and focusing on evidenced based care. This model has 
been proposed to be incorporated into cirrhosis care in the past.47 
Introducing a cirrhosis quality collaborative at each centre may also 
help meet some of these goals by incorporating quality metrics into 
the electronic health record.48 A clinical trial randomizing patients 
with decompensated cirrhosis to usual care v. pharmacist driven 
medication management and patient education is currently ongo-
ing by Hayward et al. The primary outcome of this study is medica-
tion discrepancies, but they are also evaluating adherence, quality 
of life, medication beliefs and clinical outcomes such as hospitaliza-
tions and mortality.49 All of these initiatives require systematic re-
design of how patients with decompensated cirrhosis receive care. 
Despite the challenges of cost and provider buy- in, these changes 
are essential to improve the standard of medication management 
and clinical outcomes in cirrhosis.
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